PRESS RELEASES

October 23, 2019

EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)

NEW YORK-- (BUSINESS WIRE) -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that three abstracts highlighting its Ancer™ platform have been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland.

March 25, 2019

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

NEW YORK, March 25, 2019 / PRNewswire /  EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on March 29th - April 3rd in Atlanta, Georgia. It will present data highlighting how inhibitory neoepitopes uncovered using advanced computational tools affect immune responses to therapeutic cancer vaccines.

October 22, 2018

EpiVax Oncology Appoints Dominique Bridon as Chief Technology Officer and Dan Adams to the Board of Directors

NEW YORK and PROVIDENCE, R.I., Oct. 22, 2018 (PRNewswire) -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, is pleased to announce the appointment of Dominique Bridon as Chief Technology Officer and the appointment of Dan Adams to the Board of Directors, both effective immediately.

June 12, 2018

EpiVax Oncology Raises $1.2M Bridge Financing

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC.

September 25, 2017

EpiVax Launches Precision Cancer Immunotherapy Venture, EpiVax Oncology

PROVIDENCE, R.I., Sept. 25, 2017 /PRNewswire/ -- EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. 

Please reload

© Copyright Epivax Oncology 2019